EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata

Melissa Piliang, Jennifer Soung, Brett King iD, Jerry Shapiro, Lidia Rudnicka, Paul Farrant, Nina Magnolo, Bianca Maria Piraccini, Xin Luo, Robert Wolk, Deborah Woodworth, Gregor Schaefer und 1 weitere

British Journal of Dermatology · 24.01.2025 · 192 (2) · 215-227

DOI: 10.1093/bjd/ljae365 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Dermatology, online erschienen am 21.10.2024. Verfasst von Melissa Piliang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Protein Kinase Inhibitors. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The ALLEGRO phase IIa and IIb/III (NCT02974868 and NCT03732807) studies have demonstrated that ritlecitinib is effective and well tolerated in adults and adolescents with alopecia areata (AA) up to 48 weeks.

Objectives

To assess the efficacy of ritlecitinib through month 24 and safety through data cutoff in the ALLEGRO phase IIb/III study and the ongoing long-term open-label phase III ALLEGRO-LT study (NCT04006457).

Methods

Patients aged ≥ 12 years with AA and ≥ 50% scalp hair loss from ALLEGRO IIb/III who rolled over to ALLEGRO-LT after up to 48 weeks were included. Proportions of patients with responses based on clinician-reported Severity of Alopecia Tool (SALT) scores of ≤ 20 and ≤ 10, eyebrow assessment (EBA) and eyelash assessment (ELA), patient global impression of change (PGI-C) and patient satisfaction with hair growth were reported through month 24 for patients who received ritlecitinib 50 mg daily with or without a 200-mg 4-week daily loading dose. Observed and imputed data [last observation carried forward (LOCF)] were reported up to 9 December 2022. Safety was assessed throughout.

Results

At month 12, a SALT score ≤ 20 was achieved by 45.1% and 45.9% (observed) and 40.3% and 41.8% (LOCF) of the 191 and 194 patients who received ritlecitinib 50 mg and ritlecitinib 200 mg/50 mg, respectively. At month 24, these proportions increased to 60.8% and 63.1% (observed) and 46.1% and 50.8% (LOCF), respectively. Patients with abnormal EBA or ELA scores at baseline achieved responses at month 24 [EBA observed: 57.6% (50 mg), 61.0% (200/50 mg); EBA LOCF: 46.8% (50 mg), 50.9% (200/50 mg); ELA observed: 51.2% (50 mg), 62.7% (200/50 mg); ELA LOCF: 43.2% (50 mg), 51.7% (200/50 mg)]. PGI-C response was achieved by patients at month 24 [observed: 70.0% (50 mg), 76.4% (200/50 mg); LOCF: 56.6% (50 mg), 65.5% (200/50 mg)]. Safety profiles for both treatment groups were consistent with the known safety profile of ritlecitinib.

Conclusions

Ritlecitinib has clinically meaningful and sustained efficacy beyond 1 year with a favourable safety and tolerability profile, supporting its long-term use in patients aged ≥ 12 years with AA. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataProtein Kinase InhibitorsHumansFemaleMaleAdultMiddle AgedTreatment OutcomeAdolescentYoung AdultChildAgedAdministration, Oral

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA.
  • Southern California Dermatology, Santa Ana, CA, USA.
  • Yale School of Medicine, New Haven, CT, USA.
  • New York University School of Medicine, New York, NY, USA.
  • Medical University of Warsaw, Warsaw, Poland.
  • Dermatology Department, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.

ORCID-Profile: Brett King

Förderung

  • Pfizer Inc

Zitieren

APA

Piliang, M., Soung, J., King, B., Shapiro, J., Rudnicka, L., Farrant, P., Magnolo, N., Piraccini, B. M., Luo, X., Wolk, R., Woodworth, D., Schaefer, G., & Lejeune, A. (2025). Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata. British Journal of Dermatology, 192(2), 215-227. https://doi.org/10.1093/bjd/ljae365

Vancouver

Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, et al. Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata. British Journal of Dermatology. 2025;192(2):215-227. doi:10.1093/bjd/ljae365

BibTeX
@article{Piliang2025,
  author = {Piliang, Melissa and Soung, Jennifer and King, Brett and Shapiro, Jerry and Rudnicka, Lidia and Farrant, Paul and Magnolo, Nina and Piraccini, Bianca Maria and Luo, Xin and Wolk, Robert and Woodworth, Deborah and Schaefer, Gregor and Lejeune, Alexandre},
  title = {Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata},
  journal = {British Journal of Dermatology},
  year = {2025},
  volume = {192},
  number = {2},
  pages = {215--227},
  doi = {10.1093/bjd/ljae365}
}
Kostenlos starten →